drugset / Trial / NCT03173859

Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients

NCT03173859

Phase 2 Withdrawn University of Athens
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized phase II study comparing the sequential use of abiraterone followed after progression by apalutamide with alternating cycles of abiraterone and apalutamide

Timeline

Start
2018-01
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiraterone acetate Small molecule 1000 mg Oral
Subject Apalutamide Small molecule 240 mg Oral